drugset

drugset / Trial / NCT02425904

Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders

NCT02425904 ↗

Phase 2 Active not recruiting 25 enrolled Dana-Farber Cancer Institute Cookies for Kids' Cancer · collab North American Consortium for Histiocytosis · collab Sanofi · collab St. Baldrick's Foundation · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This research study is evaluating a drug called clofarabine as a possible treatment for Langerhans Cell Histiocytosis (LCH) and and other histiocytic disorders.

Timeline

Start: 2015-05
Primary completion: 2020-01
Completion: 2026-12-31

Publications

Degar BA, Abla O, Campbell PK, Friedmann AM, Henry MM, Hermiston ML, Hogarty M, Jacobsen ED, Jubran R, Kao PC, Koch VB, Kumar AR, Ladisch S, London WB, McClain KL, Stine KC, Wistinghausen B, Rodriguez-Galindo C. Clofarabine for relapsed/refractory LCH and non-LC histiocytosis. Blood Adv. 2026 Jul 28;10(14):5087-5096. doi: 10.1182/bloodadvances.2026019922.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Clofarabine	Other / unclassified	25 mg/m2	Intravenous

Indications